Development Pipeline

Cleave has two oncology development programs for CB-5339: an internally funded program in acute myeloid leukemia (AML), and a National Cancer Institute (NCI) sponsored program in solid tumors.  INDs for these programs are expected to be filed in 2019. In addition, Cleave has an earlier stage program investigating VCP/p97 inhibitor use in neurodegenerative diseases such as VCP-Disease (also known as IBMPFD or multisystem proteinopathy) and Huntington’s Disease.